What is dNovo?
Founded in 2018, dNovo operates at the intersection of biotechnology and regenerative medicine. The company is dedicated to developing a definitive cure for baldness by utilizing advanced cell technology to regenerate hair follicles. Unlike traditional pharmaceutical approaches that focus on symptom management, dNovo's methodology centers on the biological restoration of hair-producing cells. Headquartered in Silicon Valley, the firm benefits from a robust ecosystem of scientific talent and venture capital, allowing it to maintain a competitive edge in the pre-clinical research landscape. Its market position is defined by its focus on high-impact, science-led solutions that target significant unmet needs in the global healthcare and wellness sectors.
How much funding has dNovo raised?
dNovo has raised a total of $2.7M across 1 funding round:
Angel/Seed
$2.7M
Angel/Seed (2022): $2.7M with participation from Felicis Ventures, Yintai Investment Company, Soma Capital Partners, and Y Combinator
Key Investors in dNovo
Felicis Ventures
A Menlo Park-based venture capital firm that raises multistage funds to invest in early and growth-stage technology companies across sectors such as SaaS, AI, and consumer.
Soma Capital Partners
A San Francisco-based investment firm that specializes in owning and operating commercial real estate focused on innovation and community building.
Y Combinator
A premier startup accelerator established in 2005 that provides seed funding and mentorship to high-growth technology businesses.
What's next for dNovo?
With the successful closure of this major strategic investment, dNovo is poised to scale its pre-clinical operations significantly. The immediate roadmap involves expanding laboratory capabilities and accelerating the validation of its cell-based therapies. As the company moves deeper into the development cycle, the focus will likely shift toward optimizing manufacturing processes for its biological assets and preparing for future regulatory milestones. The infusion of capital provides the necessary runway to attract top-tier scientific talent and forge strategic partnerships that will be essential for navigating the complex path toward clinical trials. Investors will be closely monitoring the firm's ability to translate its laboratory successes into scalable, safe, and effective treatments for hair loss, a market segment that continues to see high demand for innovative, long-term solutions.
See full dNovo company page
